List of Excipients in Branded Drug BENICAR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cosette Pharmaceuticals Inc	BENICAR	olmesartan medoxomil	0713-0860	CELLULOSE, MICROCRYSTALLINE
Cosette Pharmaceuticals Inc	BENICAR	olmesartan medoxomil	0713-0860	FERRIC OXIDE YELLOW
Cosette Pharmaceuticals Inc	BENICAR	olmesartan medoxomil	0713-0860	HYDROXYPROPYL CELLULOSE
Cosette Pharmaceuticals Inc	BENICAR	olmesartan medoxomil	0713-0860	HYPROMELLOSE

BENICAR Excipient Strategy and Commercial Opportunities for Olmesartan Medoxomil

Last updated: September 25, 2026

Benicar contains olmesartan medoxomil, an oral angiotensin II receptor blocker approved in the United States for hypertension. Its core commercial opportunity is no longer branded exclusivity. It is generic substitution, differentiated oral solid dosage forms, fixed-dose combinations, excipient supply, and reformulations that improve manufacturability, dissolution, tolerability, or patient adherence.

The original Benicar tablet uses conventional excipients, including lactose, cellulose-based binders and disintegrants, magnesium stearate, coating materials, and colorants. The product has no biologic component, so biosimilar risk is not applicable. Generic competition is governed primarily by ANDA approval, bioequivalence, formulation execution, supply economics, and any remaining method-of-use or formulation rights.

What is Benicar and which excipients does it contain?

Benicar is the U.S. brand name for olmesartan medoxomil tablets. Daiichi Sankyo developed and markets the product. FDA approved Benicar in 2002 under NDA 021286 for adults with hypertension and later approved pediatric use for patients aged six years and older.[1]

The marketed strengths are 5 mg, 20 mg, and 40 mg. The 5 mg strength is particularly relevant to excipient strategy because low-dose tablets create greater content-uniformity and blend-segregation risks than the 20 mg and 40 mg products.

Benicar dosage-form and excipient profile

The U.S. labeling identifies a conventional immediate-release, film-coated tablet platform. The formulation uses excipients from established oral solid-dose categories:

Formulation function	Representative Benicar excipient category
Diluent and tablet-body former	Microcrystalline cellulose
Diluent	Lactose monohydrate
Binder	Hydroxypropyl cellulose
Disintegrant	Low-substituted hydroxypropyl cellulose
Lubricant	Magnesium stearate
Film coating	Polymer, plasticizer, pigment, and opacifier system
Color	Iron oxide pigments and titanium dioxide, depending on strength

The exact qualitative and quantitative composition should be taken from the applicable FDA labeling and manufacturer regulatory file before making a substitution or infringement assessment. FDA labeling identifies inactive ingredients but generally does not provide the full commercial formula or manufacturing process.[1,2]

The formulation is strategically significant because it relies on common, globally available excipients. That reduces supply risk and supports multiple generic manufacturers, but it also limits the ability to establish strong exclusivity around the basic tablet composition.

What excipient strategy is used in Benicar tablets?

Benicar uses a low-complexity immediate-release strategy rather than a modified-release or delivery-system platform. Its commercial design priorities are likely:

1. consistent release of olmesartan medoxomil;
2. adequate tablet hardness and friability;
3. rapid disintegration;
4. acceptable content uniformity at the 5 mg strength;
5. stable film coating and color differentiation;
6. scalable direct-compression or granulation processing.

Why cellulose excipients matter

Microcrystalline cellulose provides compactibility and bulk. Low-substituted hydroxypropyl cellulose supports tablet breakup. Hydroxypropyl cellulose can improve granule cohesion and tablet mechanical strength. This combination is conventional but technically useful when the active pharmaceutical ingredient has limited dose loading or challenging flow properties.

Magnesium stearate requires process control. Excessive lubrication or prolonged blending can reduce tablet tensile strength and slow wetting or dissolution. This creates a practical development opportunity for generic manufacturers using co-processed excipients or optimized lubrication systems.

Why lactose selection matters

Lactose is an economical filler with broad regulatory acceptance. It can create compatibility, moisture, or patient-labeling considerations for certain populations. The presence of lactose also creates opportunities for lactose-free reformulations, although a lactose-free product would need to demonstrate equivalent performance and could require a new regulatory strategy if it is not a straightforward ANDA formulation.

Lactose grade, particle size, moisture content, and supplier variation can affect blend uniformity and compression behavior. A generic manufacturer may achieve manufacturing advantages through an alternate lactose grade without changing the finished product’s clinical performance.

What commercial opportunities exist for Benicar excipients?

The largest opportunity is not a new branded Benicar formulation. It is supplying or developing excipient systems for generic olmesartan medoxomil, olmesartan combinations, and differentiated oral dosage forms.

Excipient supplier opportunities

Excipient companies can target:

• co-processed microcrystalline cellulose and disintegrant systems;
• directly compressible lactose-cellulose blends;
• low-moisture excipients for improved stability;
• optimized magnesium stearate grades;
• low-peroxide and low-metal impurity excipients;
• film-coating systems that reduce coating time;
• colorant systems that maintain strength differentiation;
• excipient premixes for low-dose content uniformity.

A supplier with a validated platform can sell the same excipient system across olmesartan, losartan, valsartan, irbesartan, and other immediate-release antihypertensive tablets. This expands the addressable market beyond Benicar.

Generic manufacturer opportunities

Generic companies have several commercial routes:

Opportunity	Regulatory route	Commercial rationale
Standard olmesartan tablet	ANDA	Lowest development and approval cost
Lactose-free tablet	ANDA if pharmaceutical equivalence and bioequivalence are maintained	Differentiation for excipient-sensitive patients
Orally disintegrating tablet	505(b)(2) or other applicable pathway	Swallowability and adherence
Chewable or dispersible tablet	Often 505(b)(2)	Pediatric and geriatric positioning
Olmesartan fixed-dose combination	ANDA for listed combination or 505(b)(2)	Higher prescription value and adherence
Multiparticulate or granule product	505(b)(2)	Flexible dosing and swallowing benefit
Lower-cost manufacturing platform	ANDA	Margin expansion rather than clinical differentiation

The basic immediate-release tablet is likely to face the strongest price competition. Differentiated dosage forms can produce better margins but require stronger clinical, regulatory, and commercial justification.

When did Benicar lose exclusivity and when can generic olmesartan enter?

Benicar’s principal small-molecule exclusivity period has ended. FDA approved the first generic olmesartan medoxomil tablets in 2016, after patent litigation and settlement activity involving Daiichi Sankyo and generic applicants.[3,4]

Milestone	Approximate date
Benicar U.S. approval	2002
Pediatric indication approval	2006
Core compound patent protection	Expired in the mid-2010s
First U.S. generic approvals	2016
Current market structure	Multiple generic manufacturers and branded-generic competition

The exact launch date for a particular generic depends on the applicant, settlement terms, FDA approval timing, and commercial launch decision. Generic entry is no longer blocked by the original Benicar exclusivity position.

What is the Orange Book status of Benicar?

The Orange Book is relevant to Benicar because it records the FDA’s listed patents and regulatory exclusivity information for the reference product. The principal reference product is Benicar tablets under NDA 021286. Benicar HCT and Azor are separate products with separate applications and combination-product histories.[5]

The commercial significance of the Orange Book position is now limited compared with the pre-generic period. Core olmesartan medoxomil patent protection has expired, and generic olmesartan products are commercially established. Any remaining listed patent must be evaluated by product, strength, indication, and expiration date rather than inferred from the original Benicar approval.

Paragraph IV challenge exposure

The principal Paragraph IV period occurred before generic launch. Generic applicants challenged relevant patents to obtain earlier market access. Those disputes produced litigation and settlement activity involving Daiichi Sankyo and generic companies.[3,4]

For a new generic entrant today, the key risks are less likely to involve the original compound patent. They are more likely to involve:

• product-specific formulation patents;
• combination-product patents;
• manufacturing-process patents;
• labeling or method-of-use claims;
• patent rights associated with a differentiated dosage form;
• commercial execution against established generic suppliers.

A formulation change that creates a commercially meaningful product may also create its own patent exposure if it relies on proprietary excipient ratios, particle engineering, solid-state control, or delivery technology.

What patents protect Benicar and how strong is the patent estate?

The historic Benicar patent estate centered on olmesartan medoxomil, a prodrug converted in vivo to olmesartan. The core compound patent was associated with U.S. Patent No. 5,616,599 and expired before the current generic market was established.[3]

The remaining patent strength for a conventional Benicar-equivalent tablet is low. A routine substitution of lactose, microcrystalline cellulose, or a standard disintegrant generally offers limited patent defensibility because these excipients are widely used and their functions are well established.

Potentially stronger formulation patent positions

A new formulation patent could be more defensible if it claims a technically specific and reproducible result, such as:

• a defined particle-size distribution of olmesartan medoxomil;
• a controlled impurity profile;
• a specific solid form or amorphous dispersion;
• a narrow excipient ratio that solves a demonstrated dissolution or stability problem;
• a moisture-controlled manufacturing process;
• a novel orally disintegrating or dispersible dosage form;
• a combination of olmesartan with another antihypertensive and a defined release profile.

Patent strength depends on claim breadth, unexpected results, freedom to operate, enablement, and whether the formulation is obvious in view of the reference product and prior art. A patent that merely claims conventional excipients in predictable amounts would face a higher invalidity risk.

What formulations are protected or commercially attractive?

The strongest commercial candidates are products that address a clear patient or manufacturing problem.

Orally disintegrating and dispersible tablets

An orally disintegrating olmesartan product could target patients who have difficulty swallowing conventional tablets. The formulation would require careful control of:

• rapid disintegration;
• acceptable mouthfeel;
• mechanical strength;
• moisture sensitivity;
• taste masking;
• dose uniformity;
• packaging protection.

Because olmesartan medoxomil can have an unacceptable taste profile in an unmasked formulation, taste-masking technology could provide a stronger commercial and patent position than a simple excipient swap.

Pediatric formulations

FDA approved Benicar for pediatric hypertension, but the conventional tablet remains less flexible than a liquid or dispersible formulation. A pediatric opportunity could include a low-dose dispersible tablet, oral granules, or an age-appropriate liquid.

The main technical barriers are dose uniformity, chemical stability in suspension, preservative selection, palatability, dosing-device accuracy, and in-use stability. A pediatric formulation could proceed through a 505(b)(2) strategy if the product differs materially from the listed tablet.

Fixed-dose combinations

Olmesartan is already used in combination products, including Benicar HCT with hydrochlorothiazide and Azor with amlodipine. Generic combination products can offer better adherence and higher product value than single-agent tablets.

The excipient strategy must address the compatibility of multiple active ingredients. Hydrochlorothiazide and amlodipine can impose different particle, moisture, compression, and dissolution requirements. Bilayer tablets, separate granules, or controlled spatial distribution within the tablet may reduce incompatibility risk.

How does Benicar compare with competing antihypertensive products?

Product class	Active ingredient	Formulation competition	Excipient opportunity
Benicar	Olmesartan medoxomil	Generic immediate-release tablets; combinations	ODT, pediatric, lactose-free, process optimization
Cozaar	Losartan potassium	Large generic base; many combinations	Low-cost manufacturing and combination products
Diovan	Valsartan	Generic tablets and combinations	Solubility, flow, and fixed-dose products
Avapro	Irbesartan	Generic immediate-release tablets	Standardized excipient platforms
Micardis	Telmisartan	Generic tablets; distinctive API properties	Dissolution and solid-state control
Exforge-type products	Amlodipine plus valsartan or related ARB	Combination-tablet competition	Bilayer, taste, and dose-uniformity systems

Olmesartan’s commercial differentiation is weakened by the availability of multiple generic ARBs. A new product therefore needs a specific value proposition, such as pediatric usability, improved swallowing, lower pill burden, superior stability, or a lower manufacturing cost.

What FDA regulatory pathway applies to new Benicar formulations?

A conventional generic olmesartan tablet generally uses the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference product.[6] A product with a materially different dosage form, route, formulation, or clinical use may require a 505(b)(2) application.

The regulatory choice affects development cost, clinical requirements, labeling flexibility, and patent certification obligations.

Product concept	Likely FDA pathway
Same-strength immediate-release tablet	ANDA
Same tablet with different inactive ingredients	Usually ANDA if equivalence requirements are met
Orally disintegrating tablet	Potentially 505(b)(2)
Oral suspension	Potentially 505(b)(2)
Pediatric granules	Potentially 505(b)(2)
New fixed-dose combination	ANDA or 505(b)(2), depending on listed reference and formulation
New delivery system	Usually 505(b)(2)

A formulation must also comply with FDA inactive-ingredient expectations, pharmaceutical equivalence requirements, dissolution testing, stability requirements, and labeling obligations. FDA’s Inactive Ingredient Database can support excipient precedent and route-of-administration analysis.[7]

What manufacturing and intellectual-property barriers exist?

The main manufacturing barriers are technical rather than patent-based. They include:

• controlling low-dose blend uniformity;
• preventing segregation during transfer and compression;
• maintaining dissolution after lubrication;
• controlling moisture uptake;
• managing API particle-size variation;
• ensuring coating uniformity across strengths;
• controlling impurities from API synthesis and storage;
• securing consistent excipient grades across jurisdictions.

The main intellectual-property barriers are formulation-specific. A manufacturer should review patents and applications covering olmesartan medoxomil solid forms, particle engineering, combinations, pediatric formulations, manufacturing processes, and delivery systems.

Geographic coverage also matters. A formulation may be free to commercialize in the United States but blocked by active patents in Europe, Japan, China, or other regulated markets. U.S. Orange Book status does not establish freedom to operate globally.

What generic launch scenarios exist for Benicar?

Standard commodity launch

This is the lowest-risk route but has the weakest margin profile. Several manufacturers can produce equivalent immediate-release tablets, making price, supply reliability, and payer access decisive.

Differentiated excipient launch

A lactose-free, low-moisture, or improved-compression formulation could support modest differentiation. The commercial benefit depends on whether the product solves a recognized patient or manufacturing problem.

505(b)(2) specialty launch

An ODT, pediatric dispersible product, or oral suspension could support higher pricing and reduced direct substitution. The development program would be more expensive and may require additional clinical or bridging evidence.

Combination-product launch

Olmesartan/hydrochlorothiazide and olmesartan/amlodipine products can reduce pill burden. The principal barriers are combination-product bioequivalence, formulation compatibility, labeling, and competition from established generic combinations.

Key Takeaways

• Benicar is an olmesartan medoxomil immediate-release tablet in 5 mg, 20 mg, and 40 mg strengths.
• Its excipient system is conventional and includes lactose, cellulose-based excipients, magnesium stearate, coating materials, and colorants.
• Core Benicar exclusivity has expired, and generic olmesartan competition is established.
• The strongest commercial opportunities are generic manufacturing efficiency, ODTs, pediatric formulations, lactose-free products, and fixed-dose combinations.
• Conventional excipient substitutions offer limited patent strength unless they produce a documented, unexpected technical effect.
• Biosimilar risk does not apply because olmesartan medoxomil is a small-molecule drug.
• The key regulatory routes are ANDA for equivalent tablets and 505(b)(2) for materially differentiated dosage forms.
• Commercial success depends more on formulation performance, supply economics, payer access, and patient usability than on the original Benicar patent estate.

FAQs

Is Benicar still patent protected?

The core olmesartan medoxomil protection has expired, and generic olmesartan products are marketed in the United States. Product-specific formulation or combination patents must be reviewed separately.

Can a company sell a lactose-free generic Benicar tablet?

Potentially. The product must satisfy applicable ANDA equivalence requirements or use a different regulatory pathway if the formulation change is material.

Is olmesartan medoxomil suitable for an orally disintegrating tablet?

Yes, but the product requires taste masking, rapid disintegration, mechanical strength, moisture control, and bioequivalence or bridging support.

Does Benicar have biosimilar competition?

No. Biosimilar regulation applies to biological products. Benicar contains the small molecule olmesartan medoxomil and is subject to generic-drug regulation.

Which Benicar formulation has the best commercial potential?

A pediatric dispersible product, orally disintegrating tablet, or differentiated fixed-dose combination has greater potential than another standard immediate-release tablet because the commodity tablet market is already genericized.

References

1. U.S. Food and Drug Administration. (2023). Benicar (olmesartan medoxomil) tablets: Prescribing information. Daiichi Sankyo, Inc.

2. National Library of Medicine. (2024). DailyMed: Benicar-olmesartan medoxomil tablet, film coated. U.S. National Library of Medicine.

3. U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,616,599: Imidazole derivatives. U.S. Department of Commerce.

4. U.S. Food and Drug Administration. (2016). FDA approves first generic versions of Benicar. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

7. U.S. Food and Drug Administration. (2024). Inactive ingredient database. U.S. Department of Health and Human Services.